EPS Diluted: 3.48
Is the EPS diluted high or low?
The EPS diluted of 3.48 is 66% above its 5-year average of 2.10, around the middle of its 5-year range (0.07–5.78).
24.84% below its 12-month average of 4.63.
PODD EPS Diluted
Reported quarterly diluted EPS; no daily interpolation.
PODD Average EPS Diluted Chart
PODD Current vs Average EPS Diluted Chart
PODD EPS Diluted Metrics
EPS DILUTED
3.48
EPS DILUTED AVG TTM
4.63
EPS DILUTED AVG 3Y
3.07
EPS DILUTED AVG 5Y
2.10
EPS DILUTED AVG 10Y
0.96
EPS DILUTED AVG 15Y
-0.55
EPS DILUTED AVG 20Y
-1.03
CURRENT VS TTM AVG
-24.84%
CURRENT VS 3Y AVG
+13.49%
CURRENT VS 5Y AVG
+65.51%
CURRENT VS 10Y AVG
+260.80%
CURRENT VS 15Y AVG
+729.19%
CURRENT VS 20Y AVG
+438.68%
EPS Diluted Formula & Definition
EPS Diluted includes the effect of convertible securities, options, and other potential shares. Compare it with basic EPS to see the impact of potential dilution.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
EPS Diluted FAQ
- What is the EPS diluted for Insulet Corp. (PODD)?
- The EPS diluted for PODD stock is 3.48.
- Is Insulet Corp.'s EPS diluted high or low?
- The EPS diluted of 3.48 is 66% above its 5-year average of 2.10, around the middle of its 5-year range (0.07–5.78).
- What is the TTM average EPS diluted for Insulet Corp. (PODD)?
- The TTM average EPS diluted for PODD stock is 4.63.
- What is the 3Y average EPS diluted for Insulet Corp. (PODD)?
- The 3Y average EPS diluted for PODD stock is 3.07.
- What is the 5Y average EPS diluted for Insulet Corp. (PODD)?
- The 5Y average EPS diluted for PODD stock is 2.10.
- What is the 10Y average EPS diluted for Insulet Corp. (PODD)?
- The 10Y average EPS diluted for PODD stock is 0.96.
- What is the 15Y average EPS diluted for Insulet Corp. (PODD)?
- The 15Y average EPS diluted for PODD stock is -0.55.
- What is the 20Y average EPS diluted for Insulet Corp. (PODD)?
- The 20Y average EPS diluted for PODD stock is -1.03.
PODD EPS Diluted History
| DATE | EPS DILUTED |
|---|---|
| 2025-12-31 | 3.48 |
| 2024-12-31 | 5.78 |
| 2023-12-31 | 2.94 |
| 2022-12-31 | 0.07 |
| 2021-12-31 | 0.25 |
| 2020-12-31 | 0.10 |
| 2019-12-31 | 0.19 |
| 2018-12-31 | 0.05 |
| 2017-12-31 | -0.46 |
| 2016-12-31 | -0.50 |
| 2015-12-31 | -1.29 |
| 2014-12-31 | -0.93 |
| 2013-12-31 | -0.83 |
| 2012-12-31 | -1.08 |
| 2011-12-31 | -1.22 |
| 2010-12-31 | -1.54 |
| 2009-12-31 | -2.68 |
| 2008-12-31 | -3.36 |
| 2007-12-31 | -3.21 |
| 2006-12-31 | -39.19 |
| 2005-12-31 | -70.95 |
| 2004-12-31 | -47.64 |
| 2003-12-31 | -43.88 |
| 2002-12-31 | -42.30 |
Related Metrics
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy